Cancer-related breakthrough pain;Dolor irruptivo en cáncer

Medicina Clinica

Volumn 135, Issue 6, 2010, Pages 280-285

  Porta Sales, Josep ^a   Garzón Rodríguez, Cristina ^a   Julià Torras, Joaquín ^b   Casals Merchán, Miquel ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALFENTANIL; ANALGESIC AGENT; BUPRENORPHINE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; OPIATE; OXYCODONE; SUFENTANIL;

CANCER PAIN; DECOMPRESSION SURGERY; DISEASE CLASSIFICATION; HUMAN; NEUROMODULATION; OSTEOSYNTHESIS; PERCUTANEOUS VERTEBROPLASTY; PREVALENCE; REVIEW;

EID: 77954459659     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2010.02.008     Document Type: Article

References (60)

1. J. Porta-Sales, X. Gmez-Batiste, A. Tuca Rodrguez, F. Madrid Juan, J. Espinosa Rojas, and J. Trelis Navarro WHO analgesic ladder- or lift? J Palliat Care 10 2003 105 109
2. R.K. Portenoy, and N.A. Hagen Breakthrough pain: definition, prevalence and characteristics Pain 41 1990 273 281
3. C.L. Nekolaichuk, R.L. Fainsinger, and P.G. Lawlor A validation study of a pain classification system for advanced cancer patients using content experts: the Edmonton Classification System for Cancer Pain Palliat Med 19 2005 466 476
4. R.K. Portenoy, D. Payne, and P. Jacobsen Breakthrough pain: characteristics and impact in patients with cancer pain Pain 81 1999 129 134
5. B.V. Fortner, T.A. Okon, and R.K. Portenoy A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain J Pain 3 2002 38 44
6. Muriel Villoria C. Dolor Irruptivo: Definicin. Caractersticas. Perfil del tratamiento ideal. En: Dolor Irruptivo. Documento de Consenso. SEOM. SECPAL. SED. Meditex: Madrid; 2002; p. 278.
7. a ed 2004 Oxford Oxford University Press 438 458
8. A.N. Davies, A. Dickman, C. Reid, A.M. Stevens, and G. Zeppetella The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland Eur J Pain 13 2009 331 338
9. B.V. Fortner, G. Demarco, G. Irving, J. Ashley, G. Keppler, and J. Chavez Description and predictors of direct and indirect costs of pain reported by cancer patients J Pain Symptom Manage 25 2003 9 18
10. M. Swanwick, M. Haworth, and R.F. Lennard The prevalence of episodic pain in cancer: a survey of hospice patients on admission Palliat Med 15 2001 9 18
11. X. Gmez-Batiste, F. Madrid, F. Moreno, A. Gracia, J. Trelis, and M. Nabal Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain J Pain Symptom Manage 24 2002 45 52
12. A. Valls, M. Algara, and P. Foro Anlisis de las caractersticas tcnicas de 4.600 tratamientos con radioaciones en relacin a su finalidad teraputica Oncologia 22 1999 61 67
13. A. Caraceni, C. Martini, E. Zecca, R.K. Portenoy, M.A. Ashby, G. Hawson Working Group of an IASP Task Force on Cancer Pain Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey Palliat Med 18 2004 177 183
14. G. Zeppetella, C.A. O'Doherty, and S. Collins Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice J Pain Symptom Manage 20 2000 87 92
15. P.G. Fine, and M.A. Busch Characterization of breakthrough pain by hospice patients and their caregivers J Pain Symptom Manage 16 1998 179 183
16. B. Gagnon, P.G. Lawlor, I.L. Mancini, J.L. Pereira, J. Hanson, and E.D. Bruera The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients J Pain Symptom Manage 22 2001 826 833
17. N. Janjan, S.T. Lutz, J.M. Bedwinek, W.F. Hartsell, A. Ng, and R.S. Pieters Jr Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology J Palliat Med 12 2009 417 426
18. J.S. Wu, R. Wong, M. Johnston, A. Bezjak, and T. Whelan Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases Int J Radiat Oncol Biol Phys 55 2003 594 605
19. M. Coronado, A. Redondo, J. Coya, E. Espinosa, R.M. Couto, and P. Zamora Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease Clin Nucl Med 31 2006 605 610
20. S. Mercadante, G. Intravaia, P. Villari, P. Ferrera, S. Riina, and F. David Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids Clin J Pain 23 2007 793 798
21. M.E. Schroeder Neurolytic nerve block for cancer pain J Pain Symptom Manage 1 1986 91 94
22. W. Lavelle, A. Carl, E.D. Lavelle, and M.A. Khaleel Vertebroplasty and kyphoplasty Med Clin North Am 91 2007 299 314
23. S. Mercadante, P. Villari, P. Ferrera, and A. Casuccio Optimization of opioid therapy for preventing incident pain associated with bone metastases J Pain Symptom Manage 28 2004 505 510
24. G.W. Hanks, F. Conno, N. Cherny, M. Hanna, E. Kalso, and H.J. McQuay Morphine and alternative opioids in cancer pain: the EAPC recommendations Br J Cancer 84 2001 587 593
25. R.H. Enting, C. Mucchiano, W.H. Oldenmenger, M. Fritzon, A. Wallen, and S. Goslinga-van der Gaag The "pain pen" for breakthrough cancer pain: a promising treatment J Pain Symptom Manage 29 2005 213 217
26. Jackson KC. Opioid pharmacokinetics. In: Opioids in cancer pain. Davis M, Glare P, Hardy, editores. Oxford University Press; 2005; p. 432.
27. D. Fitzgibbon, D. Morgan, D. Dockter, C. Barry, and E.D. Kharasch Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients Pain 106 2003 309 315
28. H. Pavis, A. Wilcock, J. Edgecombe, D. Carr, C. Manderson, and A. Church Pilot study of nasal morphine-chitosan for relief of breakthrough pain in patients with cancer J Pain Symptom Manage 24 2002 598 602
29. B.A. Coda, A.C. Rudy, S.M. Archer, and D.P. Wermeling Pharmacokinetics and Bioavailability of Single-Dose Intranasal Hydromorphone Hydrochloride in Healthy Volunteers Anesth Analg 97 2003 117 123
30. N.A. Hagen, K. Fisher, and C. Stiles Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study J Palliat Med 10 2007 331 337
31. O. Dale, C. Hoffer, P. Sheffels, and E.D. Kharasch Disposition of nasal, intravenous, and oral methadone in healthy volunteers Clin Pharmacol Ther 72 2002 536 545
32. G. Zeppetella Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot sudy Palliat Med 15 2001 323 328
33. S. Blick, and A.J. Wagstaff Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer Drugs 66 2006 2387 2393
34. M. Messina, M. Darwish, and P.G. Fine Fentanyl buccal tablet Drugs Today (Barc) 44 2008 41 54
35. K.A. Overhoff, R. Clayborough, and M. Crowley Review of the TAIFUN multidose dry powder inhaler technology Drug Dev Ind Pharm 34 2008 960 965
36. G. Hanks Oral transmucosal fentanyl citrate for the management of breaktrough pain Eur J Pall Care 8 2001 6 9
37. J.B. Streisand, J.R. Varvel, D.R. Stanski, L. Le Maire, M.A. Ashburn, and B.I. Hague Absorption and bioavailability of oral transmucosal fentanyl citrate Anesthesiology 75 1991 223 229
38. K. Mystakidou, E. Katsouda, E. Parpa, L. Vlahos, and M.L. Tsiatas Oral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristics Cancer Drug Delivery 13 2006 269 276
39. L. Shaiova, J. Lapin, L.S. Manco, D. Shasha, K. Hu, and L. Harrison Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis Support Care Cancer 12 2004 268 273
40. J.T. Farrar, J. Clearly, R. Rauck, M. Busch, and E. Nordbrock Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for the treatment of breakthrough pain in cancer patients J Natl Cancer Inst 90 1998 611 616 (Pubitemid 28204805)
41. R.K. Portenoy, R. Payne, P. Coluzzi, J.W. Raschko, A. Lyss, and J.W. Raschko Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthough pain in cancer patients: a controlled dose titration study Pain 79 1999 303 312
42. R. Payne, P. Coluzzi, L. Hart, M. Simmonds, A. Lyss, and R. Rauck Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain J Pain Symp Manage 22 2001 575 583 (Pubitemid 32547445)
43. S. Durfee, J. Messina, and R. Khankari Fentanyl effervescent buccal tablets: enhhaced buccal absortion Am J Drug Deliv 4 2006 1 5
44. M. Darwish, M. Kirby, P. Robertson, W. Tracewell, and J.G. Jiang Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate J Clin Pharmacol 47 2007 343 350
45. M. Darwish, K. Tempero, M. Kirby, and J. Thompson Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers Clin Pharmacokinet 44 2005 1279 1286
46. M. Darwish, M. Kirby, J.G. Jiang, W. Tracewell, and P. Robertson Jr. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 microg in healthy subjects Clin Drug Investig 28 2008 1 7
47. S. Bredenberg, M. Duberg, B. Lennerns, H. Lennerns, A. Pettersson, and M. Westerberg In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance Eur J Pharm Sci 20 2003 327 334
48. B. Lennerns, T. Hedner, M. Holrnberg, S. Brendenberg, C. Nystrm, and H. Lennerns Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain Br J Clin Pharm Pharmacol 59 2004 149 153
49. R.L. Rauck, M. Tark, E. Reyes, T.G. Hayes, A.J. Bartkowiak, and D. Hassman Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain Curr Med Res Opin 2009 [Epub ahead of print]
50. N. Vasisht, L.N. Gever, I. Tagaroo, and A.L. Finn Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized open-label, single-dose, crossover study Clin Drug Investig 10 2009 647 654
51. Vasisht N, Stark J, Finn A. Dose linearity and absolute bioavailability of BEMATM(BioErodible MucoAdhesive) Fentanyl in healthy volunteers. American Pain Society, Annual Meeting 2008. poster 191. [disponible en: www.ampainsoc.org ] noviembre 2009
52. O. Dib, R. Kapoor, W. Reid, J. Stark, and D. Blum Absorption and tolerability of BEMA (BioErodible MucoAdhesive) fentanyl in cancer subjects with grade 1 mucositis J Clin Oncol 26 2008 (May 20 suppl; abstr 20559)
53. P. Watts, and A. Smith PecSys: in situ gelling system for optimised nasl drug delivery Drug Deliv 6 2009 543 552
54. S. Mercadante, L. Radbruch, A. Davies, P. Poulain, T. Sitte, and P. Perkins A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial Curr Med Res Opin 25 2009 2805 2815
55. S. Mercadante, L. Radbruch, L. Popper, L. Korsholm, and A. Davies Ease of use and preference for intranasal fentanyl spray (INFS) versus oral transmucosal fentanyl citrate (OTFC) for breakthrough cancer pain Eur J Pain 13 Suppl. 1 2009 S198
56. ®: onset of action, consistency, and acceptability in breakthrough cancer pain (BTCP). American Pain Society, Annual Meeting 2008. poster 244. [consultado 19/11/2009]. Disponible en: www.ampainsoc.org
57. ®: efficacy, tolerability, and onset of action in the treatment of breakthrough cancer pain (BTCP).American Pain Society, Annual Meeting 2008. poster 245. [consultado 19/11/2009]. Disponible en: www.ampainsoc.org
58. R. Schwagmeier, N. Boerger, W. Meissner, and H.W. Striebel Pharmacokinetics of intranasal alfentanil J Clin Anesth 7 1995 109 113
59. K. Jackson, M. Ashby, and J. Keech Pilot dose finding study of intranasal sufentanyl for breakthrough and incident cancer-associated pain J Pain Symptom Manage 23 2002 450 452
60. P. Good, K. Jackson, D. Brumley, and M. Ashby Intranasal sufentanil for cancer-associated breakthrough pain Palliat Med 23 2009 54 58